StockGuru Shines its Spotlight on Two Big Bio-Techs with Big News: Advanced Medical Isotope Corporation (OTCBB: ADMD) and TapImmune Inc. (OTCBB: TPIV) — October 31, 2011

StockGuru Shines its Spotlight on Two Big Bio-Techs with Big News:  Advanced Medical Isotope Corporation (OTCBB: ADMD) and TapImmune Inc. (OTCBB: TPIV) — October 31, 2011

(Dallas, TX. – October 31, 2011) StockGuru Shines its Spotlight on two big bio-tech companies making big news:

  • Advanced Medical Isotope Corporation (OTCBB: ADMD)
  • TapImmune Inc. (OTCBB: TPIV)

On Friday, October 28, 2011, these Companies announced:

TapImmune Inc. (OTCBB: TPIV) announced that the US Patent Office has issued Patent 7,994,146 entitled “Method of Enhancing an Immune Response”.  The invention relates to a method of enhancing an immune response to an antigen by augmenting the level of TAP (Transporters Associated with Antigen Processing) molecule in a target cell bearing the antigen. This patent details application to treating vaccinia, herpes simplex and influenza virus infections and small cell lung cancer. Levels of TAP in humans correlate with susceptibility to certain diseases and the ability to respond to a vaccine. Next generation smallpox and tuberculosis vaccines containing TAP genes are currently in preclinical development.  The Company closed on October 28, 2011, at $0.249, trading in a fifty-two week range of $0.39-0.12.

Advanced Medical Isotope Corporation (OTCBB: ADMD) is engaged in the production and distribution of medical isotopes.   The Company has engaged Global TechInnovations (“GTI”) for assistance in acquiring a Russian company that specializes in the production and sales of stable isotopes and critically needed industrial as well as radioactive isotopes used for medical diagnostic and therapeutic uses. With a broad base of clients worldwide, including key alliances and production capabilities, AMIC anticipates executing definitive documents prior to year-end.  The Company closed on October 28, 2011, at $0.25, trading in a fifty-two week range of $0.48-0.191.

About Advanced Medical Isotope Corporation

Advanced Medical Isotope Corporation (OTCBB: ADMD) is a company engaged in the production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic application. AMIC’s goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until recently, have not been feasible or economical, in an effort to detect and cure human disease. For more information, please visit our website,

The Advanced Medical Isotope Corporation logo is available at

About Global TechInnovations

Global TechInnovations is a for-profit global investment and professional services company, in which CDRF Global is the principal investor. GTI offers international expertise in assisting Russian and foreign experts in the field of innovative entrepreneurship. GTI provides a wide array of professional services in support of U.S. companies engaging in global expansion who seek access to advanced innovations, technology start-ups seeking access to global markets, and research organizations interested in doing R&D on a contractual basis. GTI was recently engaged by the Plug and Play Tech Center, one of the most well-known and successful Silicon Valley business incubators, to facilitate their efforts in Russia.

About United States Industry Coalition

The U.S. Industry Coalition (USIC) is a non-profit corporate membership association of high tech businesses, associations, and research institutions who are actively engaged in technology commercialization in the service of global security, peace and prosperity.

About CDRF Global

CRDF Global is an independent non-profit organization that promotes international scientific and technical collaboration through grants, technical resources, training, and services. Under the umbrella of CRDF Solutions, they offer a suite of resources that simplifies the complex process of conducting international scientific research and expanding clients’ commercial opportunities globally. CRDF Global is is based in Arlington, Virginia, with offices in Moscow, Russia; Kyiv, Ukraine; Almaty, Kazakhstan; and Amman, Jordan.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects”, “anticipates,” “continue,” “estimates,” “projects,””intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company’s control.



About TapImmune

TapImmune’s unique approach is designed to increase the efficacy of vaccines by enhancing antigen presentation through the use of the Transporter of Antigen Processing (‘TAP’). Replacement of this transporter provides a significant immune response with the potential to treat a variety of cancers which lack normal amounts of TAP. TapImmune’s lead product candidate, AdhTAP, is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently planning the development of AdhTAP for the commencement of clinical manufacturing and toxicology studies. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer. TapImmune is initiating clinical development of a multi-component vaccine for the treatment of HER-2/neu positive breast cancer.

The Company is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times. TapImmune’s TAP technology could significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases. Next generation smallpox and TB vaccines are currently in preclinical development.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K and other SEC filings which are available through EDGAR at The Company assumes no obligation to update the forward-looking statements.


To view this StockGuru Spotlight, please visit:

To get free alerts on this and other similar stocks, please register here:

What is the StockGuru Spotlight?

Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.

StockGuru looks for potential break-out candidates in The StockGuru Spotlight.  Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage.  There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below.   StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.

To feature a company in The StockGuru Spotlight please contact the Publisher at  If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact the StockGuru Publisher John Pentony at this email address: (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions.  SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage.  When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present.  Additionally SG also discloses any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

John Pentony, Publisher,

Tel: +1 469 252 3031